Brianne Dentel
Overview
Explore the profile of Brianne Dentel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dentel B, Angeles-Perez L, Flores A, Lei K, Ren C, Sanchez A, et al.
Neurobiol Dis
. 2025 Jan;
205():106790.
PMID: 39765274
Loss of function in the subunits of the GTPase-activating protein (GAP) activity toward Rags-1 (GATOR1) complex, an amino-acid sensitive negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1),...
2.
Gibson J, Vazquez A, Yamashiro K, Jakkamsetti V, Ren C, Lei K, et al.
Cell Rep
. 2023 Dec;
42(12):113533.
PMID: 38048226
Cerebellar dysfunction has been linked to autism spectrum disorders (ASDs). Although cerebellar pathology has been observed in individuals with fragile X syndrome (FXS) and in mouse models of the disorder,...
3.
Dentel B, Angeles-Perez L, Ren C, Jakkamsetti V, Holley A, Caballero D, et al.
iScience
. 2022 May;
25(5):104334.
PMID: 35602938
Targeted therapies for epilepsies associated with the mTORC1 signaling negative regulator GATOR1 are lacking. NPRL2 is a subunit of the GATOR1 complex and mutations in GATOR1 subunits, including , are...
4.
Dentel B, Escamilla C, Tsai P
Neuron
. 2020 Jan;
104(6):1032-1033.
PMID: 31951535
Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant...
5.
Hussain R, Cravens P, Doelger R, Dentel B, Herndon E, Loof N, et al.
Ann Clin Transl Neurol
. 2018 Dec;
5(12):1543-1561.
PMID: 30564621
Objective: Natalizumab blocks 4-integrin-mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML),...